Molecular pathogenesis of pancreatic cancer

Hematology/Oncology Clinics of North America

Volumn 16, Issue 1, 2002, Pages 17-35

  Hilgers, Werner ^a   Rosty, Christophe ^b   Hahn, Stephan A ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; MITOCHONDRIAL DNA; PROTEIN P16; PROTEIN P53;

CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CHROMOSOME ABERRATION; GENE INACTIVATION; GENETIC ANALYSIS; HUMAN; MOLECULAR BIOLOGY; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, MITOCHONDRIAL; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KARYOTYPING; NEOPLASM PROTEINS; NEOPLASTIC SYNDROMES, HEREDITARY; ONCOGENES; PANCREATIC NEOPLASMS; REGISTRIES;

EID: 0036262601     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(01)00005-3     Document Type: Review

References (104)

1. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome
2. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
3. Smads as transcriptional co-modulators
4. Abnormalities of the RBI and DCC tumor suppressor genes: Uncommon in human pancreatic adenocarcinoma
5. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas
6. The structural basis of molecular genetic deletions. An integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma
7. Exploring the new world of the genome with DNA microarrays
8. Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer
9. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
10. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia
11. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA
12. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer
13. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms
14. Overexpression of p53 protein in adenocarcinoma of the pancreas
15. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma
16. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer
17. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids
18. Specific chromosomal aberrations and amplification of the AIB-nuclear receptor coactivator gene in pancreatic carcinomas
19. Very high risk of cancer in familial Peutz-Jeghers syndrome
20. Increased risk of cancer in the Peutz-Jeghers syndrome
21. Normal beta-catenin gene in pancreatic cancer
22. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+
23. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas
24. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas
25. INK4 mutations
26. Consistent chromosome abnormalities in adenocarcinoma of the pancreas
27. Mutations of the DPC4/Smad4 Gene in biliary tract carcinoma
28. Homozygous deletion map at 18q21.1 in pancreatic cancer
29. DPC4. A candidate tumor suppressor gene at human chromosome 18q21.1
30. Allelotype of pancreatic adenocarcinoma using xenograft enrichment
31. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma
32. TGF-3 signaling from cell membrane to nucleus through SMAD proteins
33. Genomic FIIIT analysis m RER+ and RER- adenocarcinomas of the pancreas
34. Homozygons deletions inactivate DCC, but not MADH4/DPC4/SMAD4, in a subset of pancreatic and biliary cancers
35. High-resolution deletion mapping of chromosome arm 1p in pancreatic cancer identifies a major consensus regional at 1p35
36. Mutations in the SMAD4 DPC4 gene in juvenile polyposis
37. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions
38. K-ras encogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
39. Cyclin and cancer II: Cyclin D and CDK inhibitors come of age
40. Functional mapping of the MHI DNA-binding domain of DPC4 SMAD4
41. Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations
42. p53 and K-RAS alterations in pancreatic epithelial cell lesions
43. A cell cycle regulator potentially involved in genesis of many tumor types
44. Deleted in Colorectal Cancer (DCC) encodes a netrin receptor
45. Mutant p53 proteins bind DNA abnormally in vitro
46. Lessons from hereditary colorectal cancer
47. Relation of pancreatic duet hyperplasia to carcinoma
48. p53, the cellular gatekeeper for growth and division
49. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
50. The quest for preneoplastic lesions in the pancreas
51. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis
52. Duct changes and K-ras mutations in the disease-free pancreas: Analysis of type, age relation and spatial distribution
53. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium
54. Familial pancreatic cancer: Clinicopathologic study of 18 nuclear families
55. Familial pancreatic cancer: A review
56. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: A family study
57. TGFβ signaling: Receptors, transducers, and Mad proteins
58. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis
59. Novel germline p16(INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no. 148
60. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma
61. Frequent codeletions of p16/MTS1 and p 15/MTS2 and genetic alterations in p 16/MTS1 in pancreatic tumors
62. Analysis of PTEN/MMACI alterations in aerodigestive tract tumors
63. Proteomics to study genes and genomes
64. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions
65. Deficient DNA mismatch repair: A common etiologic factor for colon cancer
66. Somatic mutations of the mitochondrial genome in human colorectal tumours
67. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions
68. Normal SMAD2 gene in pancreatic cancer
69. Tumor-suppressive pathways in pancreatic carcinoma
70. INK4 genes in pancreatic carcinoma
71. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas
72. DPC4 gene in various tumor types
73. DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression
74. Smad4/ DPC4-mediated tumor suppression through suppression of angiogenesis
75. Genetic characterization and cloning of Mothers against dpp, a gene required for decapentaplegic function in Drosophila melonagaster
76. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
77. Allelotype of pancreatic adenocarcinonm
78. Cancer cell cycles
79. Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA binding in TGF-beta signaling
80. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome
81. Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization
82. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts
83. ACVR1B1ALK4. Activin receptor type 1B) gene mutations in pancreatic carcinoma
84. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene
85. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers
86. K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers
87. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease
88. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo
89. Human mitogen-activated protein kinase kinase4 as a candidate tumor suppressor
90. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer
91. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers
92. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families
93. Neoplastic diseases in families of breast cancer patients
94. Serial analysis of gene expression
95. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene
96. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene
97. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression
98. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity
99. Loss of expression of DPC4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression
100. No endoglin mutations in pancreatic ductal adenocarcinoma
101. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability
102. Genetic progression and divergence in pancreatic carcinoma
103. Human Smad3 and Smad4 are sequence-specific transcription activators